Disseminated intravascular coagulation: epidemiology, biomarkers, and management

被引:114
作者
Adelborg, Kasper [1 ,2 ,3 ]
Larsen, Julie B. [1 ]
Hvas, Anne-Mette [1 ,3 ]
机构
[1] Aarhus Univ Hosp, Dept Clin Biochem, Palle Juul Jensens Blvd, DK-8200 Aarhus N, Denmark
[2] Aarhus Univ Hosp, Dept Clin Epidmiol, Aarhus, Denmark
[3] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
关键词
disseminated intravascular coagulation; thrombosis; haemorrhage; sepsis; neoplasms;
D O I
10.1111/bjh.17172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disseminated intravascular coagulation (DIC) is a systemic activation of the coagulation system, which results in microvascular thrombosis and, simultaneously, potentially life-threatening haemorrhage attributed to consumption of platelets and coagulation factors. Underlying conditions, e.g. infection, cancer, or obstetrical complications are responsible for the initiation and propagation of the DIC process. This review provides insights into the epidemiology of DIC and the current understanding of its pathophysiology. It details the use of diagnostic biomarkers, current diagnostic recommendations from international medical societies, and it provides an overview of emerging diagnostic and prognostic biomarkers. Last, it provides guidance on management. It is concluded that timely and accurate diagnosis of DIC and its underlying condition is essential for the prognosis. Treatment should primarily focus on the underlying cause of DIC and supportive treatment should be individualised according to the underlying aetiology, patient's symptoms and laboratory records.
引用
收藏
页码:803 / 818
页数:16
相关论文
共 138 条
[1]   Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].
Abraham, E ;
Reinhart, K ;
Svoboda, P ;
Seibert, A ;
Olthoff, D ;
Dal Nogare, A ;
Postier, R ;
Hempelmann, G ;
Butler, T ;
Martin, E ;
Zwingelstein, C ;
Percell, S ;
Shu, V ;
Leighton, A ;
Creasey, AA .
CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089
[2]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[3]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[4]   Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review [J].
Vincent, JL ;
Abraham, E ;
Esmon, C ;
Hack, CE .
CRITICAL CARE MEDICINE, 2000, 28 (09) :S33-S33
[5]   Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults [J].
Adamzik, Michael ;
Eggmann, Martin ;
Frey, Ulrich H. ;
Goerlinger, Klaus ;
Broecker-Preuss, Martina ;
Marggraf, Guenter ;
Saner, Fuat ;
Eggebrecht, Holger ;
Peters, Juergen ;
Hartmann, Matthias .
CRITICAL CARE, 2010, 14 (05)
[6]   THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION: SUBANALYSIS FROM THE PHASE 3 TRIAL [J].
Aikawa, Naoki ;
Shimazaki, Shuji ;
Yamamoto, Yasuhiro ;
Saito, Hidehiko ;
Maruyama, Ikuro ;
Ohno, Ryuzo ;
Hirayama, Akio ;
Aoki, Yoshikazu ;
Aoki, Nobuo .
SHOCK, 2011, 35 (04) :349-354
[7]   Time course of platelet counts in critically ill patients [J].
Akca, S ;
Haji-Michael, P ;
de Mendonça, A ;
Suter, P ;
Levi, M ;
Vincent, JL .
CRITICAL CARE MEDICINE, 2002, 30 (04) :753-756
[8]   Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis [J].
Allingstrup, Mikkel ;
Wetterslev, Jorn ;
Ravn, Frederikke B. ;
Moller, Ann Merete ;
Afshari, Arash .
INTENSIVE CARE MEDICINE, 2016, 42 (04) :505-520
[9]   New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores [J].
Angstwurm, MWA ;
Dempfle, CE ;
Spannagl, M .
CRITICAL CARE MEDICINE, 2006, 34 (02) :314-320
[10]  
Asakura Hidesaku, 2016, Thromb J, V14, P42